Current Edition

Risk-based Monitoring Through COVID-19 and Beyond

Risk-based monitoring (RBM) may be a relatively recent phenomenon, but it has become a commonly used methodology in clinical trials as evidence of its benefits has grown when compared with the limitations of source data verification. Steven Thys at SGS Life Sciences analyses how RBM is particularly relevant during the COVID-19 pandemic, because it not only uses remote solutions, but it also offers guidance on how to deal with change in ongoing trials.